# Pediatric Arthritis Treatments AbbVie Expands RINVOQ to Children With Active pJIA By Mursal Rahman | Written with AI assistance | Published 2026-09-22 | Lifestyle Source: Trend Hunter, https://www.trendhunter.com/trends/rinvoq-oral-solution References: [prnewswire](https://www.prnewswire.com/news-releases/abbvie-announces-european-commission-approval-of-rinvoq-upadacitinib-for-the-treatment-of-children-with-active-polyarticular-juvenile-idiopathic-arthritis-302885190.html)  Pediatric arthritis treatments are expanding with the European Commission’s approval of AbbVie’s RINVOQ for patients ages two and older with active polyarticular juvenile idiopathic arthritis. The approval introduces both a 15 mg tablet and a weight-based 1 mg/mL oral solution, providing an administration option for younger patients who may have difficulty swallowing tablets. RINVOQ can be used alone or with methotrexate for eligible patients who have responded inadequately to or cannot tolerate certain existing treatments. For AbbVie, the approval extends an established immunology medicine into a younger patient population while broadening its potential reach across immune-mediated conditions. RINVOQ is now approved for 11 indications in the European Union, giving AbbVie opportunities to leverage an existing therapy across multiple patient groups. The pediatric formulation also demonstrates how age-adapted delivery formats can help pharmaceutical companies expand established treatment portfolios. Image Credit: AbbVie ## Trend Insights (Trend Hunter) - Score: 7.0/10 - Popularity: 49% | Activity: 69% | Freshness: 92% - Audience gender: 50% men, 50% women - Primary generations: Gen Z, Gen Alpha - Top markets: Europe ## Categories [Trend Hunter](https://www.trendhunter.com/trends) > [Lifestyle](https://www.trendhunter.com/lifestyle) > [Health](https://www.trendhunter.com/health) ## Key Themes ### What's Driving This Trend - **Pediatric Precision Formulations:** Age-adapted drug formats such as oral solutions are reshaping treatment access for children who cannot use standard adult dosage forms. - **Expanded Immunology Indications:** Established immune-mediated therapies are gaining new commercial relevance as approvals extend across additional diseases and patient groups. - **Child-friendly Biopharma Delivery:** Medication design centered on pediatric usability creates differentiation for pharmaceutical companies competing in chronic disease markets. ### Who This Affects Most - **Pharmaceuticals:** Portfolio expansion through pediatric approvals highlights new revenue potential for existing therapies with proven clinical foundations. - **Pediatric Healthcare:** Specialized treatment options for juvenile autoimmune conditions are improving care pathways for younger patients with complex chronic needs. - **Biotechnology:** Innovation in targeted immunology treatments supports development of more adaptable therapies across age groups and inflammatory disease categories. ## Related on Trend Hunter - [Naproxen-Powered Pain Relief Medications](https://www.trendhunter.com/trends/tylenol-with-naproxen.md) - [Pediatric-Studied Supplements](https://www.trendhunter.com/trends/saffron-kids-trends.md) - [Charitable Arthritis Relief Campaigns](https://www.trendhunter.com/trends/arthritis-awareness-month.md) - [Intravenous Biosimilar Pharmaceutical Products](https://www.trendhunter.com/trends/biosimilar-pharmaceutical-product.md) - [Movement Supporting Supplements](https://www.trendhunter.com/trends/bone-and-joint-support.md) - [Youth Arthritis Challenges](https://www.trendhunter.com/trends/the-arthur-tut.md) - [Eu-Wide Biosimilar Drug Expansions](https://www.trendhunter.com/trends/biosimilar-drug.md) - [Bio-Optimized Pain Relivers](https://www.trendhunter.com/trends/relivaid.md) - [Non-Opioid Chronic Pain Treatments](https://www.trendhunter.com/trends/nonopioid-treatment.md)